Home > Insider Trading > Filing (0001062993-23-023291)

Filing Details

Accession Number:: 0001062993-23-023291
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-12-29 17:24:55
Reporting Period:: 2023-12-27

Accepted Time:: 2023-12-29 17:24:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1620463	Athira Pharma Inc.	ATHA	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1164426	Joseph Edelman	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1224962	Perceptive Advisors Llc	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1249675	Ltd Fund Master Sciences Life Perceptive	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-12-27	32,134	$2.28	4,829,412	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-12-28	409,598	$2.44	5,239,010	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-12-29	163,954	$2.38	5,402,964	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.195 to $2.31, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.265 to $2.50, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.295 to $2.44, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor and a director of the Issuer. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.